Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series
Objective: To explore the benefits of adding eculizumab for the treatment of refractory autoimmune thrombotic thrombocytopenic purpura (iTTP) with complement dysregulation. Patients and Methods: From January 1, 2014, through July 1, 2017, we identified patients with iTTP defined by ADAMTS13 (disinte...
Main Authors: | Shebli Atrash, MD, Appalanaidu Sasapu, MD, Soumya Pandey, MD, Michele Cottler-Fox, MD, Pooja Motwani, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-03-01
|
Series: | Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2542454817301285 |
Similar Items
-
Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura
by: Alexis Boneparth MD, et al.
Published: (2015-01-01) -
Thrombotic thrombocytopenic purpura concomitant with autoimmune thyroiditis
by: Ali Bay, et al.
Published: (2011-12-01) -
Thrombotic Thrombocytopenic Purpura
by: Nuchanat Nonsee, et al.
Published: (2015-02-01) -
Educational Case: Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies and Potential Role of the Spleen
by: Meredith M. Nichols MD, et al.
Published: (2021-03-01) -
Thrombotic Thrombocytopenic Purpura and Gemcitabine
by: Pashtoon Murtaza Kasi
Published: (2011-03-01)